Regeneron Pharmaceuticals, Inc. (REGN)

543.56
NASDAQ
Prev Close 555.79
Day Low/High 533.23 / 556.58
52 Wk Low/High 303.49 / 664.64
Exchange NASDAQ
Shares Outstanding 106.39B
Market Cap 59.13B
P/E Ratio 21.54
Div & Yield N.A. (N.A)

Regeneron upgraded at Citi

A Momentum Monsters Manifesto

This strategy is a hedge against momentum-oriented money managers -- nothing more, nothing less.

Biotech Remains on Fast Track

Biotech Remains on Fast Track

Even after a run, some stocks still offer growth.

John Carter Analysis: TSLA, SLV, PFE, QIHU, BIDU, REGN, TLT & SPY

John Carter Analysis: TSLA, SLV, PFE, QIHU, BIDU, REGN, TLT & SPY

We start the short week with some thoughts on TSLA earnings and the recent move in SLV. We also drill down into a few of our favorite stocks in whats otherwise a very uncertain market.

Momentum Monsters (Part 2)

Momentum Monsters (Part 2)

Here are the next five names on my gunner-stock list.

A Surprising Leaderboard

A Surprising Leaderboard

These sectors have shown some fight.

Regeneron downgraded at Oppenheimer

I'll Still Trumpet These Stocks

I'll Still Trumpet These Stocks

I like living, breathing examples of growth stocks going right.

A Nutty Environment

A Nutty Environment

Sometimes the facts just don't fit the story.

Names in the News

Tesla, GM, Annie's, Regeneron, and Sprint are all making headlines. By Bret Jensen Tesla Motors (TSLA) has been in the news recently for its move into China. CEO Elon Musk (never the shy one) states that sales in the Middle Kingdom could equal those...

Time to Consider Some Shorts

Time to Consider Some Shorts

Here are some candidates on my watch list.

A Gift-Wrapped Buy Entry

A Gift-Wrapped Buy Entry

Regeron's technicals -- and the current pullback -- all add up to a buy.

These Stocks Deserve Faith

These Stocks Deserve Faith

Believe in CEOs with a history of winning seasons.

Where to Buy in 2014: Part II

Where to Buy in 2014: Part II

Here are four more themes where you can put money to work.

Off the Charts

Off the Charts

Cliffs Natural Resources is on our watch-list after forming a rounding bottom.

Time to Reconsider Sector Weights

Time to Reconsider Sector Weights

Rather than follow the crowd, I want to lead it.

Off the Charts

Off the Charts

We add Baidu to our long watch-list today as it holds higher at upper levels.

Is There Still a Play to Be Made on Regeneron?

Is There Still a Play to Be Made on Regeneron?

An inverse head and shoulders pattern could soon develop.

Big Pharma Emerges From the Wilderness

Big Pharma Emerges From the Wilderness

These four names are soaring, and I'd jump into all of them, even after their recent runs.

Washington Driving These Stock Ideas

Washington Driving These Stock Ideas

Auto-loan regulation could rattle some publicly traded auto dealers.

Stock Bargains Left on the Table

Stock Bargains Left on the Table

Skittish buyers are only nibbling and leaving plenty of good cheap stocks for you.

Cramer: The Top-Calling Finally Arrives

Cramer: The Top-Calling Finally Arrives

Apparently it's 'bad' now that the public has stopped pulling reams of money out of the market.

Rate Scares Are Ruling the Market

Rate Scares Are Ruling the Market

Treasuries are calling the tune today, regardless of companies' fundamentals.

ECB Won't Cut Interest Rates

ECB Won't Cut Interest Rates

Though data suggest a softer eurozone recovery than expected, EverBank's Frank Trotter says it's unlikely the ECB will cut rates.

Easy Choices in the Pharma Patch

Easy Choices in the Pharma Patch

Merck is shunned by all; Biogen is liked by all; and Bristol-Myers is the holy grail.

Cramer: It's a Shame About Washington

Cramer: It's a Shame About Washington

We're getting positive news from businesses all over the place -- yet none of it will matter if the U.S. defaults.

Understanding the Highflying Stocks

Understanding the Highflying Stocks

When forces line up against them, they tend to fall hard.

Cramer's 2,000th Mad Money Episode

Cramer's 2,000th Mad Money Episode

Jim Cramer reflects on 2,000 episodes for Mad Money and the importance of individual stock picking.